We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A potential COVID-19 treatment that uses mesenchymal stem cells (MSCs) has flown under the radar thus far, but the therapy has shown promise in early research, and phase 2/3 results that will likely come out in early fall could show that it’s a game changer. Read More
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is developing a weakened strain of SARS-CoV-2 for use in human challenge trials in case they’re needed to fully evaluate COVID-19 vaccine and therapeutic candidates, though the institute says the controversial studies would not replace phase 3 trials. Read More
The U.S. government has chosen distribution giant McKesson as a “central distributor” of COVID-19 vaccines and supplies needed to administer them once an approval or emergency authorization is granted. Read More
To produce components needed for their COVID-19 vaccine candidates, Novavax has enlisted support from a South Korean biotech, while Johnson & Johnson has agreed to work with an Indian biopharma company. Read More
The House Select Subcommittee on the Coronavirus Crisis is questioning how vaccines are being chosen for accelerated development under the U.S. government’s Operation Warp Speed and calling for details on possible conflicts of interest among those who are making the choices. Read More
AstraZeneca has entered into an agreement with mAbxience of the INSUD Group to produce AZ’s COVID-19 vaccine for most of Latin America from manufacturing facilities in Mexico and Argentina. Read More